Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
PEGylated IL2 and tumor-targeted radiotherapy augment CD8+ T cell-mediated anti-tumor response to anti-PD-1 in head and neck squamous cell carcinoma.
Journal: Theranostics
Published: March 28, 2026
Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.
Journal: Lancet (London, England)
Published: March 06, 2026
NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.
Journal: Blood advances
Published: March 14, 2025
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
Journal: Urologic oncology
Published: June 26, 2024
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 05, 2024
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
Journal: Nature communications
Published: May 16, 2024
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 31, 2023
Etirinotecan Pegol Treatment for Patients With Metastatic Breast Cancer and Brain Metastases-Reply.
Journal: JAMA oncology
Published: September 22, 2022
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
Journal: JAMA oncology
Published: May 13, 2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Journal: Journal for immunotherapy of cancer
Published: February 27, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Journal: Future oncology (London, England)
Published: January 25, 2022
Last Updated: 09/26/2026